Biomedical subjects

C Botte

Publications and source records attributed to C Botte.

4 recordsLinked to original sources

PubMed1999

Prevalence of GBV C/HGV RNA and GBV C/HGV antibodies in French volunteer blood donors: results of a collaborative study.

BACKGROUND AND OBJECTIVES: Posttransfusion hepatitis still occurs at an incidence of about 1 in 118,000 for HBV and 1 in 220,000 for HCV. This collaborative study aimed to determine the prevalence of a novel flavivirus, GBV-C/HGV, even though its role in transfusion-associated hepatitis is uncertain. MATERIALS AND METHODS: GBV-C/HGV RNA was detected by PCR using either the Boehringer detection kit or by primers previously described. HGV antibodies were detected by a serological assay from Boehringer. RESULTS: The observed GBV-C/HGV RNA frequency was 3.4%. HGV antibodies occurred in 9.5% of donors. CONCLUSION: In our study, 12. 9% of the donors had been in contact with the GBV-C/HGV virus.

Adolescent↗

PubMed1997

[Rheologic study of the dissociation reaction of erythrocyte immunologic agglutinates: application to subgroup A erythrocytes].

Red blood cell Agglutinates can be dissociated by providing enough energy which may be supplied by shear stress in a viscometer. In this paper a new technique is proposed to determine dissociation parameters of erythrocyte immunological agglutinates by using a laser backscattering method. Backscattered light intensity increases during the process of agglutinate dissociation when a controlled shear stress in a transparent Couette viscometer is applied. The obtained curves of dissociation can be fitted by an exponential function. A numerical integration of the dissociation curves allows us to obtain a parameter associated to the energy used in the dissociation process. A satisfactory differentiation of erythrocyte sub-groups Al, Az, A,B and Am has been carried out using this technique.

Blood Viscosity↗

PubMed1993

[Seroprevalence of hepatitis C antibodies among blood donors. Study of second generation ELISA and RIBA tests and surrogate markers].

Between March and November 1991, prevalence of hepatitis C antibodies was evaluated in 60,960 blood donors from the North-East of France. Using a second generation ELISA, 424 donors (0.69%) were reactive, with no significant difference between males (0.69%) and females (0.70%). Among these 424 donors, respectively 137 (32.3%), 86 (20.3%) and 201 (47.4%) were reactive, indeterminate or nonreactive by a second generation RIBA (RIBA-2) (Recombinant Immunoblot Assay). Donors with a high ELISA ratio (> or = 4) were significantly more likely to have a reactive RIBA-2. Of the 1906 donors with anti-HBc positivity (3.12%), 44 had a reactive ELISA; of these, respectively 27, 12 and 5 had a reactive, indeterminate and nonreactive RIBA. Of the 1201 donors (1.97%) with increased serum ALAT (alanine-amino-transferase) levels (> or = 2N), 42 had a positive ELISA; of these, respectively 35, 2 and 5 had a reactive, indeterminate and nonreactive RIBA. Of the 54 donors with both indirect markers, nine had a reactive ELISA; the same nine donors had a reactive RIBA. These data show that donors with both surrogate markers and a reactive ELISA are very likely to have a positive RIBA. Seventy-seven (18.16%) of the 424 donors with a reactive ELISA had at least one surrogate marker; 67 of these donors (30.04%) were among the 223 donors with a reactive ELISA and a reactive or indeterminate RIBA.

Biomarkers↗

PubMed1992

[Hepatitis C virus].

Hepatitis C Virus, major causative agent of parenterally transmitted non-A non-B hepatitis was identified by Choo et al. in 1988 using molecular biology technologies. This virus contains a positive stranded RNA genome, it has been shown to have a small diameter. These structure and properties suggest that HCV shares many features in common with Pestiviruses and Flaviviruses. After many years of research, two major objectives were reached: -the identification of viral genome and the main purified viral polypeptide derived from recombinant yeast. Major information were recently appearing about the nucleotide sequences of different isolates coming from US, Europe and Japan; -the preparation of specific tool (ELISA anti-HCV) for detection of circulating HCV antibodies.

Genome, Viral↗